{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:05:07Z","timestamp":1790719507624,"version":"4.1.0"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1093\/jac\/dkx543","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T15:08:37Z","timestamp":1514646517000},"page":"1439-1451","source":"Crossref","is-referenced-by-count":75,"title":["Clinical review of delafloxacin: a novel anionic fluoroquinolone"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-6366","authenticated-orcid":false,"given":"Bryan T","family":"Mogle","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Upstate Medical University Hospital, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M","family":"Steele","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Upstate Medical University Hospital, Syracuse, NY, USA"},{"name":"Department of Pharmacology, Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Upstate Medical University, Syracuse, NY, USA"},{"name":"Department of Microbiology and Immunology, Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KarenBeth H","family":"Bohan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-096X","authenticated-orcid":false,"given":"Wesley D","family":"Kufel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Upstate Medical University Hospital, Syracuse, NY, USA"},{"name":"Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA"},{"name":"Department of Medicine, Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"key\n\t\t\t\t20180518035552_dkx543-B1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjmed.2004.09.015","article-title":"Fluoroquinolone prescribing in the United States: 1995 to 2002","volume":"118","author":"Linder","year":"2005","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B2","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1086\/428051","article-title":"The quinolones: past, present, and future","volume":"41","author":"Andriole","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1155\/1999\/378394","article-title":"The new fluoroquinolones: a critical review","volume":"10","author":"Zhanel","year":"1999","journal-title":"Can J Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s15010-012-0257-2","article-title":"Resistance surveillance studies: a multifaceted problem \u2013 the fluoroquinolone example","volume":"40","author":"Dalhoff","year":"2012","journal-title":"Infection"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/0019-5545.39762","article-title":"Levofloxacin-induced acute psychosis","volume":"50","author":"Moorthy","year":"2008","journal-title":"Indian J Psychiatry"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.0000000000000846","article-title":"Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study","volume":"83","author":"Etminan","year":"2014","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/phar.1761","article-title":"Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk?","volume":"36","author":"Bidell","year":"2016","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/cit439","article-title":"Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan","volume":"57","author":"Chou","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B12"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B13","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two Phase 3 studies of acute bacterial skin and skin structure infections","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B15","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B17","author":"Burak","year":"2010"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B18","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/428052","article-title":"Mechanisms of resistance to quinolones","volume":"41","author":"Jacoby","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dkh242","article-title":"ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model","volume":"54","author":"Firsov","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.49.4.1633-1635.2005","article-title":"Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens","volume":"49","author":"Hermsen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B24","doi-asserted-by":"crossref","first-page":"2771.","DOI":"10.1128\/AAC.48.7.2771-2777.2004","article-title":"In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms","volume":"48","author":"Almer","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B26","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance","volume":"60","author":"Soge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B27","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/AAC.00941-16","article-title":"In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/dkh304","article-title":"The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae","volume":"54","author":"Hammerschlag","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B29","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1128\/AAC.47.12.3973-3975.2003","article-title":"Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1179\/joc.2004.16.3.227","article-title":"In vitro activity of ABT-492 against anaerobic bacteria","volume":"16","author":"Sillerstr\u00f6m","year":"2004","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B32","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1128\/AAC.47.9.3008-3011.2003","article-title":"In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B33","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B34","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.juro.2015.01.094","article-title":"Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae","volume":"194","author":"So","year":"2015","journal-title":"J Urol"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.44.2.283-286.2000","article-title":"Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"44","author":"Tomioka","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B37","author":"Bortolon","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens","volume":"48","author":"Thabit","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B39","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1128\/AAC.00647-16","article-title":"In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model","volume":"60","author":"Lepak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B40","first-page":"S429","article-title":"Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin","volume":"17","author":"Ding","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B41","author":"Knapp","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B42","author":"Koeth","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B43","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B44","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B45","author":"Levaquin (levofloxacin) [Package Insert]","year":"2008"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinthera.2015.10.016","article-title":"Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B48","author":"Data on file"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B49","author":"Hoover","year":"2013"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B50","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcph.817","article-title":"Clinical pharmacology of delafloxacin in patients with hepatic impairment","volume":"57","author":"Hoover","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B51","author":"Cipro (ciprofloxacin) [Package Insert]","year":"2004"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B52","author":"Avelox (moxifloxacin) [Package Insert]","year":"2010"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B53","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3109\/00498254.2015.1042946","article-title":"Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration","volume":"45","author":"McEwen","year":"2015","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B54","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.clinthera.2017.04.009","article-title":"The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin","volume":"39","author":"Paulson","year":"2017","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B55","first-page":"1208","volume-title":"The Merck Manual of Diagnosis and Therapy","author":"Schlecht","year":"2011"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4172\/2153-2435.1000214","article-title":"Optimizing antibiotic pharmacodynamics for clinical practice","volume":"4","author":"Connors","year":"2013","journal-title":"Pharmaceut Anal Acta"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B57","author":"Burak","year":"2009"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized Phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"O\u2019Riordan","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B59","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B60","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B61","author":"O\u2019Riordan","year":"2016"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B62","author":"Hansen","year":"2016"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B63","author":"Shah","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B64","author":"Kerney","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B65","author":"Giordano","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B66","author":"Beasley","year":"2017"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B67","author":"Longcor","year":"2012"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B68"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B69","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2133.1990.tb01819.x","article-title":"Ciprofloxacin-induced photosensitivity: in vitro and in vivo studies","volume":"123","author":"Ferguson","year":"1990","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B71","author":"Ferguson","year":"2015"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.diagmicrobio.2013.02.020","article-title":"Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus","volume":"76","author":"Ray","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B73","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jac\/dkg009","article-title":"Microbiology of polymicrobial abscesses and implications for therapy","volume":"50","author":"Brook","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B74","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/JCM.00551-07","article-title":"Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents","volume":"45","author":"Citron","year":"2007","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B75","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1469-0691.2006.01400.x","article-title":"Management of infections of osteoarticular prosthesis","volume":"12","author":"Barber\u00e1n","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B77","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1179\/joc.2007.19.6.682","article-title":"Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty","volume":"19","author":"Metallidis","year":"2007","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B78","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B79","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2016.07.013","article-title":"Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections","volume":"48","author":"Kutob","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B81","author":"Melinta Therapeutics, Inc"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B82","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B83","author":"Melinta Therapeutics, Inc"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B84","author":"Melinta Therapeutics, Inc"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B85","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B86","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/163.6.1279","article-title":"Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus","volume":"163","author":"Blumberg","year":"1991","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180518035552_dkx543-B87","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI18535","article-title":"Antimicrobial resistance: the example of Staphylococcus aureus","volume":"111","author":"Lowy","year":"2003","journal-title":"J Clin Invest"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/6\/1439\/24804689\/dkx543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T17:58:49Z","timestamp":1570557529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/6\/1439\/4841775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":87,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,2,7]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx543","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,2,7]]}}}